30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
Leukemia/lymphoma development in IL-15-deficient TCR-transgenic mice
Journal for ImmunoTherapy of Cancer volume 3, Article number: P67 (2015)
Sporadic mouse tumor models are valuable tools to understand disease development and treatment efficacies. Here we show that a transgenic T cell receptor expression predisposes mice to leukemia/lymphoma development. Leukemia/lymphoma precursors expressed low amounts of MHC class I and were deleted by NK cells in immunocompetent mice resulting in increased tumor frequency under NK cell absence. Leukemias/lymphomas were clonal and regrow after transfers into NK cell-deficient hosts. Phenotypically, most leukemias/lymphomas were positive for CD3 and CD8, and all expressed high levels of the co-stimulatory molecules PD1, ICOS and CD28 as well as of CD30 resembling the phenotype of immature CD8 single-positive thymocytes. Half of the leukemias/lymphomas harbored Notch1 mutations. Dendritic cells appear to have an auxiliary role in leukemia/lymphomagenesis since their deletion caused decreased tumor growth. The study of leukemias/lymphomas in IL-15-deficient TCR-transgenic mice may help to further understand T cell lymphomagenesis, the role of lymphoma environment, and may be useful to design and test treatments.
About this article
Cite this article
Dubois, S., Mueller, J., Feigenbaum, L. et al. Leukemia/lymphoma development in IL-15-deficient TCR-transgenic mice. j. immunotherapy cancer 3 (Suppl 2), P67 (2015). https://doi.org/10.1186/2051-1426-3-S2-P67